Literature DB >> 30683166

Creation of a novel algorithm to identify patients with Becker and Duchenne muscular dystrophy within an administrative database and application of the algorithm to assess cardiovascular morbidity.

Jonathan H Soslow1, Matthew Hall2, W Bryan Burnette3, Kan Hor4, Joanne Chisolm4, Christopher Spurney5, Justin Godown1, Meng Xu6, James C Slaughter6, Larry W Markham1.   

Abstract

BACKGROUND: Outcome analyses in large administrative databases are ideal for rare diseases such as Becker and Duchenne muscular dystrophy. Unfortunately, Becker and Duchenne do not yet have specific International Classification of Disease-9/-10 codes. We hypothesised that an algorithm could accurately identify these patients within administrative data and improve assessment of cardiovascular morbidity.
METHODS: Hospital discharges (n=13,189) for patients with muscular dystrophy classified by International Classification of Disease-9 code: 359.1 were identified from the Pediatric Health Information System database. An identification algorithm was created and then validated at three institutions. Multi-variable generalised linear mixed-effects models were used to estimate the associations of length of stay, hospitalisation cost, and 14-day readmission with age, encounter severity, and respiratory disease accounting for clustering within the hospital.
RESULTS: The identification algorithm improved identification of patients with Becker and Duchenne from 55% (code 359.1 alone) to 77%. On bi-variate analysis, left ventricular dysfunction and arrhythmia were associated with increased cost of hospitalisation, length of stay, and mortality (p<0.001). After adjustment, Becker and Duchenne patients with left ventricular dysfunction and arrhythmia had increased length of stay with rate ratio 1.4 and 1.2 (p<0.001 and p=0.004) and increased cost of hospitalization with rate ratio 1.4 and 1.4 (both p<0.001).
CONCLUSIONS: Our algorithm accurately identifies patients with Becker and Duchenne and can be used for future analysis of administrative data. Our analysis demonstrates the significant effects of cardiovascular disease on length of stay and hospitalisation cost in patients with Becker and Duchenne. Better recognition of the contribution of cardiovascular disease during hospitalisation with earlier more intensive evaluation and therapy may help improve outcomes in this patient population.

Entities:  

Keywords:  Becker muscular dystrophy; Duchenne muscular dystrophy; Pediatric Health Information System; arrhythmia; cardiomyopathy; left ventricular dysfunction

Mesh:

Year:  2019        PMID: 30683166      PMCID: PMC6433485          DOI: 10.1017/S1047951118002226

Source DB:  PubMed          Journal:  Cardiol Young        ISSN: 1047-9511            Impact factor:   1.093


  17 in total

1.  Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation.

Authors:  Michelle Eagle; Simon V Baudouin; Colin Chandler; David R Giddings; Robert Bullock; Kate Bushby
Journal:  Neuromuscul Disord       Date:  2002-12       Impact factor: 4.296

2.  Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy.

Authors: 
Journal:  Pediatrics       Date:  2005-12       Impact factor: 7.124

3.  Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy.

Authors:  Christopher Spurney; Reiko Shimizu; Lauren P Morgenroth; Hanna Kolski; Heather Gordish-Dressman; Paula R Clemens
Journal:  Muscle Nerve       Date:  2014-05-14       Impact factor: 3.217

4.  The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy.

Authors:  G Nigro; L I Comi; L Politano; R J Bain
Journal:  Int J Cardiol       Date:  1990-03       Impact factor: 4.164

5.  Prevalence and incidence of Becker muscular dystrophy.

Authors:  K M Bushby; M Thambyayah; D Gardner-Medwin
Journal:  Lancet       Date:  1991-04-27       Impact factor: 79.321

6.  Duchenne muscular dystrophy: continuous noninvasive ventilatory support prolongs survival.

Authors:  John R Bach; Daniel Martinez
Journal:  Respir Care       Date:  2011-02-11       Impact factor: 2.258

7.  Duchenne muscular dystrophy: a 30-year population-based incidence study.

Authors:  Joseph Dooley; Kevin E Gordon; Linda Dodds; Judith MacSween
Journal:  Clin Pediatr (Phila)       Date:  2010-02       Impact factor: 1.168

8.  Managing Duchenne muscular dystrophy--the additive effect of spinal surgery and home nocturnal ventilation in improving survival.

Authors:  Michelle Eagle; John Bourke; Robert Bullock; Mike Gibson; Jwalant Mehta; Dave Giddings; Volker Straub; Kate Bushby
Journal:  Neuromuscul Disord       Date:  2007-05-08       Impact factor: 4.296

9.  Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry.

Authors:  David M Connuck; Lynn A Sleeper; Steven D Colan; Gerald F Cox; Jeffrey A Towbin; April M Lowe; James D Wilkinson; E John Orav; Leigha Cuniberti; Bonnie A Salbert; Steven E Lipshultz
Journal:  Am Heart J       Date:  2008-03-19       Impact factor: 4.749

10.  The burden of Duchenne muscular dystrophy: an international, cross-sectional study.

Authors:  Erik Landfeldt; Peter Lindgren; Christopher F Bell; Claude Schmitt; Michela Guglieri; Volker Straub; Hanns Lochmüller; Katharine Bushby
Journal:  Neurology       Date:  2014-07-02       Impact factor: 9.910

View more
  3 in total

1.  Health Care Use of Cardiac Specialty Care in Children With Muscular Dystrophy in the United States.

Authors:  Erika J Mejia; Kimberly Y Lin; Oluwatimilehin Okunowo; Katherine A Iacobellis; Susan E Matesanz; John F Brandsema; Carol A Wittlieb-Weber; Hannah Katcoff; Heather Griffis; Jonathan B Edelson
Journal:  J Am Heart Assoc       Date:  2022-04-12       Impact factor: 6.106

2.  Chart validation of an algorithm for identifying hereditary progressive muscular dystrophy in healthcare claims.

Authors:  Xiaoxue Chen; Abiy Agiro; Ann S Martin; Ann M Lucas; Kevin Haynes
Journal:  BMC Med Res Methodol       Date:  2019-08-09       Impact factor: 4.615

3.  Validation of diagnostic codes and epidemiologic trends of Huntington disease: a population-based study in Navarre, Spain.

Authors:  Esther Vicente; Ainara Ruiz de Sabando; Fermín García; Itziar Gastón; Eva Ardanaz; María A Ramos-Arroyo
Journal:  Orphanet J Rare Dis       Date:  2021-02-10       Impact factor: 4.123

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.